Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,105 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,105 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05. Following the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, May 15th, Steven Leonard Chapman sold 6,779 shares of Natera stock. The stock was sold at an average price of $107.08, for a total transaction of $725,895.32.
• On Monday, April 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $380,383.76.
• On Tuesday, April 23rd, Steven Leonard Chapman sold 2,552 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76.
• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $240,698.04.

Natera Price Performance

NASDAQ:NTRA opened at $107.99 on Wednesday. The firm’s fifty day moving average price is $101.73 and its 200 day moving average price is $83.16. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $117.23. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.16. The company had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business’s revenue was up 52.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.23) EPS. Sell-side analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale purchased a new stake in shares of Natera in the 1st quarter worth about $83,000. Cetera Advisors LLC purchased a new stake in shares of Natera in the 1st quarter worth about $442,000. Cetera Investment Advisers boosted its position in shares of Natera by 514.9% in the 1st quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company’s stock worth $1,802,000 after buying an additional 16,496 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Natera by 13.0% in the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock worth $359,226,000 after buying an additional 452,800 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Natera in the 1st quarter worth about $707,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. BTIG Research increased their target price on shares of Natera from $100.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research note on Friday, April 5th. The Goldman Sachs Group raised their price objective on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Canaccord Genuity Group lifted their price target on shares of Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Finally, StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.